The risk for nephrogenic systemic fibrosis was low among patients with chronic kidney disease who received a gadolinium-based contrast agent, a study found.

AVP-R, formally known as nephrogenic diabetes insipidus, is a condition that affects the kidneys. AVP-R occurs when the kidneys no longer respond to AVP and fail to retain water.